Severe muscle damage seen in patient treated with abacavir and lipid-lowering fibrate

This article is more than 19 years old. Click here for more recent articles on this topic

Doctors from Paris have described a case of severe muscle damage in an HIV-positive patient taking abacavir and the lipid-lowering drug ciprofibrate (Modalim). The case report was published in the 4th November edition of AIDS.

Although hypersensitivity to abacavir is known to occur in 5 to 8% of patients, this case raises fears that it may be aggravated by a drug commonly used to treat high blood fat levels – itself a side-effect of antiretroviral therapy. However, the report must be treated with caution as it only describes one patient’s experiences with these drugs.

The 48 year-old man had been taking ciprofibrate for almost three years. After a two-year treatment interruption, he began a triple nucleoside reverse transcriptase inhibitor (NRTI) combination of AZT (zidovudine), 3TC (lamivudine) and abacavir as Trizivir. He had previously taken two other antiretroviral drug regimens, both of which contained AZT and 3TC.

Glossary

lipid

Fat or fat-like substances found in the blood and body tissues. Lipids serve as building blocks for cells and as a source of energy for the body. Cholesterol and triglycerides are types of lipids.

hypersensitivity

An allergic reaction.

rash

A rash is an area of irritated or swollen skin, affecting its colour, appearance, or texture. It may be localised in one part of the body or affect all the skin. Rashes are usually caused by inflammation of the skin, which can have many causes, including an allergic reaction to a medicine.

case report

Describes the medical history of a single patient.

reverse transcriptase

A retroviral enzyme which converts genetic material from RNA into DNA, an essential step in the lifecycle of HIV. Several classes of anti-HIV drugs interfere with this stage of HIV’s life cycle: nucleoside reverse transcriptase inhibitors and nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). 

After eight days of Trizivir treatment, the man complained of fever, but continued to take his anti-HIV drug combination. Two days later, he had a temperature of 40°C, skin rash, high heart rate, high breathing rate, kidney failure, and evidence of damage to muscle and liver cells. There were no signs of infection.

He was treated in intensive care and both antiretroviral therapy and ciprofibrate were stopped. Although the markers of muscle damage increased over the next few days, the fever and skin rash disappeared after 48 hours.

Kidney failure resolved after 45 days.

“Severe rhabdomyolysis [muscle damage] has never been described during a hypersensitivity reaction to abacavir or during concomitant therapy with abacavir and a lipid-lowering drug,” the authors write.

“Special attention should be paid to signs of rhabdomyolysis when abacavir therapy is started in a patient who is already receiving a lipid-lowering drug,” they warn.

References

Fontaine C et al. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. AIDS 19: 1927-1928, 2005.